How to buy Arcutis Biotherapeutics stock

Arcutis Biotherapeutics, Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 54 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.

How to buy shares in Arcutis Biotherapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Arcutis Biotherapeutics. Find the stock by name or ticker symbol: ARQT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arcutis Biotherapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arcutis Biotherapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Arcutis Biotherapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Arcutis Biotherapeutics share price

Use our graph to track the performance of ARQT stocks over time.

Arcutis Biotherapeutics shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$17.51 - USD$39.8527
50-day moving average	USD$30.42
200-day moving average	USD$27.8103
Wall St. target price	USD$56.83
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.1466

Buy Arcutis Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arcutis Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Arcutis Biotherapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcutis Biotherapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-42.95%
Return on equity TTM	-72.93%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$1.4 billion

TTM: trailing 12 months

Shorting Arcutis Biotherapeutics shares

There are currently 1.9 million Arcutis Biotherapeutics shares held short by investors – that's known as Arcutis Biotherapeutics's "short interest". This figure is 19% up from 1.6 million last month.

There are a few different ways that this level of interest in shorting Arcutis Biotherapeutics shares can be evaluated.

Arcutis Biotherapeutics's "short interest ratio" (SIR)

Arcutis Biotherapeutics's "short interest ratio" (SIR) is the quantity of Arcutis Biotherapeutics shares currently shorted divided by the average quantity of Arcutis Biotherapeutics shares traded daily (recently around 196520.40169133). Arcutis Biotherapeutics's SIR currently stands at 9.46. In other words for every 100,000 Arcutis Biotherapeutics shares traded daily on the market, roughly 9460 shares are currently held short.

However Arcutis Biotherapeutics's short interest can also be evaluated against the total number of Arcutis Biotherapeutics shares, or, against the total number of tradable Arcutis Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcutis Biotherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Arcutis Biotherapeutics shares in existence, roughly 40 shares are currently held short) or 0.0622% of the tradable shares (for every 100,000 tradable Arcutis Biotherapeutics shares, roughly 62 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcutis Biotherapeutics.

Find out more about how you can short Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics share dividends

We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.

Arcutis Biotherapeutics overview

Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Frequently asked questions

• What percentage of Arcutis Biotherapeutics is owned by insiders or institutions?

  Currently 5.22% of Arcutis Biotherapeutics shares are held by insiders and 82.707% by institutions.

• How many people work for Arcutis Biotherapeutics?

  Latest data suggests 54 work at Arcutis Biotherapeutics.

• When does the fiscal year end for Arcutis Biotherapeutics?

  Arcutis Biotherapeutics's fiscal year ends in December.

• Where is Arcutis Biotherapeutics based?

  Arcutis Biotherapeutics's address is: 3027 Townsgate Road, Westlake Village, CA, United States, 91361

• What is Arcutis Biotherapeutics's ISIN number?

  Arcutis Biotherapeutics's international securities identification number is: US03969K1088

• What is Arcutis Biotherapeutics's CUSIP number?

  Arcutis Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 03969K108